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Summary
The knowledge of disease biology as well as the therapeutic
landscape in multiple myeloma (MM) has expanded expo-
nentially in recent years. These advances have seen improve-
ments in survivorship, not only in the clinical trial setting
but also in the real setting. Importantly there is also every
evidence to indicate that such improvements in our under-
standing and treatments will continue. This article is not
intended to be a comprehensive review; rather it aims to give
a temporal context to these developments with exemplars,
and highlight the central role that UK clinicians, healthcare
workers, scientists and most importantly patients and their
relatives have played in this revolution.
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I (CM) started working in Belfast in 1968 under Prof. M. G.
Nelson at a time when melphalan had been recently intro-
duced for multiple myeloma (MM), and completed my MD
thesis in 1975 under the guidance of Drs Tom McNeill and
John Bridges. Returning to the Belfast City Hospital in 1978
after a two-year fellowship in Sydney Hospital working with
Prof. Fred Gunz and the inspirational Dr Paul Vincent, I
joined forces with Dr Jeffrey Robertson, developing autolo-
gous transplantation in Northern Ireland. I was instrumental
in developing the UK Myeloma Forum, a society for UK clini-
cians, healthcare workers and scientists, (UKMF: www.ukmf.
org.uk), which led the way in popularising disease-focused
meetings for haematologists. I chaired the EBMT Chronic
Malignancy Working Party Plasma Cell Disorders subcommit-
tee and since ’retirement’ I have continued some clinical work
on a part-time basis, mainly at Altnagelvin Hospital.
I (GC) was introduced to MM through Prof. Ian Franklin
in 1992, who mentored me through my PhD and higher
specialist training. I then moved to Leeds in 2002 to work
with Prof. Tony Child, Prof. Gareth Morgan and Prof. Julia
Brown in clinical trials. At the time of becoming interested
in MM, clinical care and trial innovation were sedentary
though were about to undergo an exponential change both
in treatment options and clinical trials (see below). Though
the United Kingdom had a prominent heritage in myeloma
clinical trials, as such we were not an established trials col-
laborative, able to compete internationally especially in the
era of novel agents. I set up the Myeloma Research Alliance
(UKMRA; www.ukmf.org.uk/clinical-trials-2/uk-mra/) in
2014, which has grown year-on-year in its impact, engender-
ing engagement, especially with young researchers to harness
the quality of clinical academics in the United Kingdom.
Development of the field
Therapeutics
Following the first description of MM,1 therapeutic interven-
tions which ranged from rhubarb and orange peel infusions
to therapeutic venesection, quinine, camphor, Dover’s pow-
ders and urethane, were of limited value.2 Melphalan had
been introduced for MM in the early 1960s but for haema-
tologists, MM was still considered the ’heart sink’ disease as
responses were limited with treatment toxicities (cytopenias)
and disease-related morbidity being significant issues. Treat-
ment certainly had limited impact on the progression of
myeloma-related end organ toxicity such as bone disease and
chronic renal impairment.3 In the early MRC Adult Leukae-
mia Working Party Myeloma trials alternative alkylating
agents (with or without prednisone) were trialled against or
in combination with melphalan but with no real improve-
ment on the 24–30 months median survival of that era.4
However, the MRC Myeloma V trial led to the ABCM com-
bination [adriamycin, BCNU (bis-chloroethylnitrosourea),
cyclophosphamide and melphalan] becoming briefly the UK
’gold standard’ though the use of oral weekly cyclophos-
phamide (C-weekly) performed surprisingly well, especially
in patients with cytopenias.5 A summary of the MRC/NCRI
trials and their major findings is presented in Table I.
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Table I. Summary baseline characteristics for the MRC/NCRI trials.
Trial Years n Age
Sex %
male Allocation
n
(randomised) Outcome
I* 1964–1968 276 – Cont. Cyclo PO
Cont. Mel PO
No significant difference
II* 1968–1975 372 – Cont. Cyclo PO
7-day PO Mel (M7) Q6-8/52
7-day PO Mel Q6-8/52 + Pred
No significant difference
III* 1975–1980 485 <75 Iv Cyclo Q3/52
M7 + Pred Q3/52
Iv Cyclo Q3/52
Cy/Mel/CCNU/Pred Q4/52
No significant difference
IV* 1980–1982 522 <80 M7 + P
M7 + PV
No significant difference
Hydration very important
V* 1982–1986 691 621 (84) 551 C-wkly plts < 80
M7
ABCM
61
316
314
ABCM superior
C-wkly useful with low toxicity
VI* 1986–1991
1991–1993
712
299
616 (81) 579 ABCM
ABCM-P
HDM (M140)
HDMP
NR ABCM
342
342
15
13
299
No significant difference
VII* (TE) 1993–2000 401 548 (48) 556 ABCM
HDM + ASCT
200
201
HDM + ASCT superior
VIII* (TNE) 1993–2002 592 675 (48) 581 ABCM
ABCM + C-wkly
NR
167
164
261
No significant difference
IX* (TE) 2003–2007 1111 578 (74) 623 Clo + CVAD
Clo + CTD
Zol + CVAD
Zol_CTD
278
278
278
277
CTD superior
Zol superior
IX*
(TNE)
2003–2007 849 734 (55) 557 Clo + MP
Clo + CTDa
Zol + MP
Zol + CTDa
211
212
212
214
CTDa superior
Zol superior
X† (REL) 2008–2012 297 60 70 PAD + HDM/2nd ASCT
PAD + Intensive C-wkly
89
85
PAD effective in 1st relapse
ASCT superior
XI† (TE) 2010–2014 1512 591 (81) 592 CTD
CRD
CVD for poor responders
R and RZ maintenance
756
756
CRD improves PFS and OS
Addition of CVD improves PFS and OS
R maintenance improves PFS and OS
XI† (TNE) 2010–2015 1852 745 (54) 565 CTDa
RCDa
CVD for poor responders
R and RZ maintenance
924
928
R maintenance improves PFS
XI+† (TE) 2013–2016 1056 598 (80) 609 CTD
CRD
KCRD
R maintenance
265
265
526
KRCD improves PFS
MP, melphalan, prednisolone; C-wkly plts, cyclophosphamide-weekly for low platelets; M7, melphalan; ABCM, doxorubicin, carmustine, cyclophos-
phamide and melphalan; HDM, high-dose melphalan; HDM + ASCT, high-dose melphalan and autologous stem cell support; Clo, clodronic acid; Zol,
zoledronic acid; CTD, cyclophosphamide, thalidomide and dexamethasone; CVAD, cyclophosphamide, vincristine, doxorubicin and dexamethasone;
PAD, bortezomib (PS-341) adriamycin and dexamethasone; CTDa, attenuated oral CTD; CRD, cyclophosphamide, lenalidomide and dexamethasone;
CRDa, attenuated oral CRD; CVD cyclophosphamide, bortezomib and dexamethasone; Cyclo, cyclophosphamide; R, lenalidomide maintenance; RZ,
combination lenalidomide and vorinostat maintenance; KCRD, carfilzomib, cyclophosphamide, lenalidomide and dexamethasone; TE, transplant eligi-
ble; TNE, transplant non-eligible; REL, relapse (previously transplanted patients); NR, nonrandomised patients; MEL, melphalan; P, prednisolone;
Pred, prednisolone; HDMP, High dose melphalan prednisolone; PV, vincristine prednisolone; C, cyclophosphamide; CCNU, Cyclophosphamide;
Cyclo, Cyclophosphamide.
*Medical Research Council (MRC) trial.
†National Cancer Research Institute (NCRI) trial.
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It was clear that alkylating agents were efficacious in MM
and a major evolution of alkylator therapy came in the 1980s
with Prof. Tim McElwain’s seminal papers describing high-
dose melphalan (HDMel: 100–140 mg/m2) in MM, obtaining
deep and lasting responses.6,7 The main toxicity was pro-
found myelosuppression of prolonged duration, leading to a
procedural-related mortality of 20–25%. This resulted in the
development of autologous stem cell support (ASCT) to
allow safe delivery of HDMel, firstly with harvested bone
marrow then subsequently cytokine-mobilised blood-derived
stem cells in the 1990s.8,9 Initially this was used to manage
relapsed and refractory disease (RRMM) but efficacy was
rapidly established in de novo disease in successive random-
ized trials. The first such study was carried out by the Inter-
groupe Francophone du Myelome (IFM) in the landmark
IFM90 trial which showed a clear-cut benefit to the ASCT
cohort.10 Other research collaborative groups demonstrated a
significant benefit in disease control (progression-free sur-
vival; PFS) but few demonstrated overall survival benefit
(OS).11,12 The issue was effectively settled by the large MRC
Myeloma VII study led by Prof. Tony Child in which ABCM
was compared to c-VAMP plus ASCT which showed con-
vincing benefit in achieving complete response (CR), pro-
gression-free survival (PFS) and overall survival (OS).13 With
successive therapeutic advances (see below) ASCT has been
tested for its relevance in the treatment algorithm and
remains an important part of myeloma therapy as ran-
domised clinical trials assessing new interventions against the
addition of ASCT have resulted in superior PFS and/or OS
for the ASCT strategy, despite the well-recognised long-term
complications associated with HDMel.14,15,16
Allogenic transplantation (allo-SCT) has been performed
in a small proportion of patients throughout this period but
the potential benefits were marred by regimen-related toxic-
ity and graft-versus-host disease in the pursuit of the putative
graft-versus-myeloma effect.17,18 However a limited number
of studies have now been reported showing that the benefits
of allo-SCT may be obtained by combining a reduced-inten-
sity allo-SCT with a prior ASCT (auto–allo) thus reducing
the transplant-related mortality, although benefit for the
autoz–allo group only became obvious after five-year follow-
up.18,19 It is of interest that only now are we closer to har-
nessing a targeted immunotherapy-based therapeutic strategy
in myeloma with the evolution of CAR T-cells and bi-specific
T-cell engager (BiTE) technology in MM.
During the first decade of this century salvage ASCT
(sASCT; defined as the use of a second ASCT after disease
has progressed following a first, initial ASCT) was being used
regularly in relapsed patients young and fit enough to
undergo a repeat procedure, often with a variable length of
first remission.20,21 It became clear there was a need for
robust clinical-trial-based evidence to establish if this was an
appropriate therapeutic approach. The UKMF/BSBMT Mye-
loma X study defined that a sASCT not only improved the
second-line PFS, it also augmented OS, with no significant
cost in a patient’s reported quality of life.22,23,24 In the fol-
low-up UKMRA Myeloma XII trial, now nearing completion
of recruitment, patients relapsing after an initial ASCT
receive a novel oral proteasome inhibitor (PI) and
immunomodulatory drug (IMiD) combination (see below)
before proceeding to a sASCT, with a randomization to stan-
dard HDMel or PI-augmented HDMel to augment depth of
response (NCT03562169).
As well as ASCT the therapeutic landscape has changed
within a generation, (revolution rather than evolution?) from
the use of a single high dose of alkylating therapy to the
widespread use of complex small molecules targeting intra-
cellular signalling pathways and manipulating immune acti-
vation networks. The empirical cytotoxic therapy of the last
century has mostly given way, firstly to therapy directed at
known intracellular pathways, for example PIs (the proteo-
some), Imids (multiple targets) and histone deacetylase inhi-
bitors (HDACs, e.g. pabinostat). In the last decade we have
witnessed the identification of specific surface and intracellu-
lar targets with the development of agents to specifically tar-
get them, for example, CD38 – daratumumab; Exportin-1
(XPO1) – selinixor25 and B-cell maturation antigen (BMCA)
– GSK2857916 antibody-drug conjugate.26 Figure 1 illustrates
the gain in OS obtained by incorporation of newer agents
into successive MRC trials.27 While much of the develop-
ment of these new agents has taken place in the USA, the
United Kingdom has been involved through British scientists
working both in the United Kingdom and abroad, and also
through clinical trial participation in all the major licensing
trials, for example Apex – bortezomib28; MM003 – lenalido-
mide29; Pollux – daratumumab plus lenalidomide30; Castor –
daratumumab plus bortezomib31; Tourmaline32 – elo-
tuzumab33 and Eloquent – ixazomib.34
This dramatic change in the treatment algorithm over the
last two decades started with the discovery of the anti-MM
effect of thalidomide when it was empirically tested in
RRMM.35 This discovery of a ’new class’ of drugs led to
efforts to really understand the underlying biology behind
thalidomide’s anti-MM effect and to develop safer and more
potent versions of thalidomide. These agents are now
referred to as IMiDs.36 Thalidomide very quickly became a
front-line agent, and the NCRI Myeloma IX was the large
phase III study that demonstrated the impact of replacing
infusional chemotherapy with thalidomide plus steroids and
cyclophosphamide (CTD).37,38,39 However, the vast majority
of MM patients still relapse, and the search for further novel
agents continued. With the introduction of the first in class
PI, bortezomib, in 2003 anti-MM therapy entered the age of
sub-cellular pathway targeted therapy. The UK contributed
significantly during the clinical development of bortezomib,
but of particular note was Prof. Jamie Cavenagh’s inspira-
tional blending of the old and the new, substituting borte-
zomib for vincristine in the VAD-like schedule [PAD:
bortezomib (PS341) adriamycin and dexamethasone]. This
regime was highly effective in newly diagnosed patients as
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well as being effective in relapsed patients and was incorpo-
rated into the NCRI Myeloma X trial for sASCT at first
relapse.40,41,42,23
Lenalidomide, the first of the second-generation IMiDs,
demonstrated significant efficacy, especially with dexametha-
sone, without the quality of life-limiting side effects of
thalidomide and became established as treatment for RRMM
and subsequently a front-line therapy for ASCT-ineligible
patients.29,43,44 As well as being involved in the global regula-
tory studies, the UK contributed to the efficacy data through
the NCRI Myeloma XI trial, led by Prof. Graham Jackson.
This was the largest front-line study in MM ever, successfully
defining the role of lenalidomide maintenance.45 The UK has
been involved in the clinical development pathways of the
other second-generation (pomalidomide) and third-genera-
tion IMiDs.46,47,48,36,49
The breakthrough therapeutic development of note in the
current decade has been the development and licensing of
the monoclonal antibody that targets CD38-expressing cells,
daratumumab.50 Though there is modest single-agent activ-
ity, the combination of daratumumab with PIs and IMiDs
has seen some remarkable efficacy signals in clinical trials,
initially in RRMM but also in front-line therapy30,51,52,31.
Currently, there are some 50–60 agents being actively investi-
gated in clinical trials, many with diverse mechanisms of
action and distinct targets, including cellular therapies, mon-
oclonal antibodies, small molecules (such as venetoclax and
the nuclear transport inhibitor selinexor) and now
immunotherapies [CAR T cells, BiTE, CAR NK (natural
killer] cells] are being investigated.53,54,55
Biomarker discovery
As a consequence of a very successful clinical trials portfolio
and allied translational work, researchers in MM have been
able to define predictive biomarkers, and the United King-
dom has been at the forefront, in particular in the arena of
genomic risk biomarkers, minimal residual disease (MRD)
detection and clinical frailty scores.
MM is a genetically complex disease that develops in a
multistep process with the primary genetic events including
chromosomal translocations involving the immunoglobulin
heavy-chain genes (IGH) and aneuploidy with subsequent,
secondary genetics events including copy number abnormali-
ties, DNA hypomethylation and acquired mutations leading
to tumour progression.56 Since the early 2000s there has been
an exponential growth of knowledge pertaining to genomic
and molecular characterisation of MM with the technical
advances from metaphase karyotyping and fluorescent in situ
hybridisation (FISH) to more high-throughput technologies
0
20
40
60
80
10
0
Time from randomisation (m)
O
S
 (%
)
0 12 24 36 48 60
IV
V
VI
VII
VIII
IX(TE)
OS Estimate [95%CI]
IV
V
VI
VII
VIII
IX(TE)
71·3 [67·5, 75·2] 52·6 [48·5, 57] 37·4 [33·5, 41·7] 27·1 [23·6, 31·2] 19·7 [16·6, 23·4]
69·5 [66·2, 73·1] 54·2 [50·6, 58·1] 38·5 [35, 42·3] 27·1 [24, 30·7] 18 [15·3, 21·1]
75 [72·4, 77·8] 58·9 [55·9, 62] 43·8 [40·8, 46·9] 33·1 [30·3, 36·2] 25·1 [22·5, 27·9]
81·5 [77·8, 85·4] 69·6 [65·2, 74·2] 60·3 [55·7, 65·3] 50·1 [45·4, 55·3] 43·3 [38·7, 48·5]
73 [69·5, 76·7] 54·4 [50·5, 58·6] 38·7 [34·8, 42·9] 29·2 [25·6, 33·3] 20·9 [17·6, 24·7]
93·8 [92·6, 95] 87·5 [85·8, 89·2] 80·9 [78·9, 82·9] 73·7 [71·5, 76] 67·1 [64·7, 69·6]
Fig 1. Overall survival of patients admitted into successive MRC/NCRI clinical trials.
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such as gene expression profiling (GEP), next generation
sequencing (NGS), whole genome and whole exome sequenc-
ing, leading to a better appreciation of MM biology and its
implications in therapy.57
Using FISH, the primary genetic abnormalities in MM
include translocations primarily involving the IgH gene locus
on chromosome 14 (14q32.33) with one of several partner
chromosomes including chromosomes 4, 6, 11, 14 and 20.57
With the exception of t(11;14), these balanced translocations
confer a poorer outcome with therapy.58 The deletion of
chromosome 17p, affecting the tumour suppressor gene,
TP53, has been highlighted as adversely affecting survivor-
ship.59 More recently abnormalities of chromosome 1 have
been defined as a genetic risk adversely affecting survivor-
ship, especially del 1p and gain 1q. Moreover, MM displays
significant clonal heterogeneity which can impact presenta-
tion and drug sensitivity, durability of response to modern
therapies and most importantly survivorship.60
The use of trial-based sampling with associated clinical out-
come data has advanced our understanding in the biology of
MM and has been critical to assess its true impact. Here, the
United Kingdom has led the field, through the work of Prof.
Fiona Ross, Prof. Gareth Morgan and latterly, Dr Martin Kai-
ser using samples and outcome data from the large frontline
phase III trials conducted in the UK (Myeloma VII, IX, X and
XI).61,62,63 The collective evidence has highlighted the predic-
tive biomarker status of genetic aberrations, and has defined
three categories of risk: standard risk, high risk (one of the
above-mentioned lesions) and ultra-high risk (two or more
lesions) with a clear-cut influence on PFS and OS.64
Response biomarkers have become more important over
the last two decades with the advent of more targeted and
effective anti-MM therapies. It is increasingly recognised that
the deeper the response to treatment, the more durable the
effect, possibly even affecting survivorship.65 However, where
once attaining a CR was the aim of therapy, more recently
becoming MRD-negative (a deeper response than CR) is
associated with even better outcomes, hence MRD detection
has become increasingly important. Advances in technology,
from the improvements in the sensitivity of flow cytometery
(MFC) to detect small populations of malignant cells (from
104 to 106) to the utility and practical delivery of NGS to
provide a molecular basis for MRD, has focused clinical
attention on measurement of MRD and provided new thera-
peutic goals.66,67,68 Arguably, the largest clinical dataset
reflecting the impact of MRD detection by MFC has been
generated by Dr Roger Owen and Dr Andy Rawstron from
the large front-line phase III trials conducted in the United
Kingdom (Myeloma VII, IX and XI).69,70,71 Achievement of
MRD-negative status following treatment is associated with a
significant improvement in PFS and OS.72 This large-cohort
meta-analysis identified MRD status as a marker of long-
term survival outcome in patients with MM, establishing it
as a suitable predictive biomarker in MM and an appropriate
end-point in clinical trials.
Patients with MM are at risk of therapy-related toxicity,
particularly the transplant non-eligible (TNE), as a result of
the complex interplay of age, physical function, cognitive
function and comorbidity. The International Myeloma
Working Group proposed a scoring system (IMWG FS) for
MM patient frailty that predicts survival, adverse events and
treatment tolerability using age, the Katz Activity of Daily
Living (ADL), the Lawton Instrumental Activity of Daily Liv-
ing (IADL) and the Charlson Comorbidity Index (CCI),
which was tested and validated in clinical-trial populations.73
The UKMRA generated a more laboratory-based objective
risk score incorporating age, PS, CRP and ISS which was able
to discriminate not only therapy-related toxicity and regimen
completion but survivorship and impact on quality of life.74
Although more of a risk score than a traditional frailty score,
it nonetheless defined patient populations who are vulnerable
in the treatment setting. It has also been tested and validated
in clinical trial populations and has since been replicated in a
real-world setting.75
Supportive care
While much has been achieved in anti-MM therapy, the role
of supportive care has also evolved. Almost one in three MM
patients present as emergencies with advanced disease caus-
ing serious morbidity.76 The sequelae may be renal failure
and/or hypercalcaemia for which prompt therapy is beneficial
to acute presentations but a significant proportion develop
chronic kidney disease.77 One of the earliest findings from
the MRC studies was that maintaining good hydration could
improve renal health and certainly help to prevent further
renal deterioration.78 Indeed, the advice to drink 3 l of fluid
per day is still relevant and useful today. The United King-
dom has also been pivotal in demonstrating the benefit of
bisphosphonates in the management of myeloma bone dis-
ease initially through the work of Prof. Graham Russell79 and
in studies linked to the MRC/NCRI trials, the benefits of clo-
dronate80,81 and subsequently zolodronic acid,82,83 now
accepted internationally as a standard of care. Unfortunately,
we remain (as yet) unable to promote healing of these
lesions. Erythropoietin is now accepted for therapy-induced
anaemia but no remedy has been found for the fatigue which
often accompanies effective therapy with IMiDs and other
novel agents. Despite extensive use of systemic anticoagulants
thromboembolic events remain a problem particularly in
IMiD-treated patients.84 Happily, despite the trend to ever
more intensive therapy quality of life does not appear to be
adversely affected.22,85 Longer survivals have meant that
extra-medullary disease (EMD) is seen more often, usually as
a late finding, often containing a new clone of the disease,
and these progressions are frequently difficult to manage.86,87
Particularly in older/frail patients, early death remains a
problem, most commonly as a consequence of infection.74
The UK TEAMM trial has demonstrated the benefit of pro-
phylactic antibiotics in the early months of treatment and
BRITISH SOCIETY FOR HAEMATOLOGY 60TH ANNIVERSARY SPECIAL ISSUE
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd 5
this approach needs to be incorporated into routine manage-
ment.88
Collaborative working
The pace of scientific and therapeutic discovery has increased
exponentially over the past two decades and has necessitated
working more actively and collaboratively by myeloma pro-
fessionals. Started by a small group of myeloma enthusiasts
and under first the chairmanship of Prof. Tony Child fol-
lowed by Dr Diana Sampson and then Dr Steve Schey the
UK Myeloma Forum is a group for medical, nursing, scien-
tific and other professionals working in the field of myeloma.
It has established two regular high-quality one-day meetings
per year with an endowment facilitating speakers from Eur-
ope and North America. It actively promoted the existing
MRC/NCRI trials but recognising the lack of Phase 2 trials
and the associated access to new therapeutic agents, and
working with Eric Low of the patient support group, Mye-
loma United Kingdom (MUK), we established the MUK
early trials portfolio which supported 10 Phase I and II stud-
ies (Table II). From its early days UKMF has also been active
in producing high-quality evidence-based guidelines on a
range of myeloma topics. This has reflected the collegial and
inclusive nature of the UK myeloma community. These
guidelines, all adopted by the British Society for Haematol-
ogy and published in this journal, have been an effective
form of training and basis of good practise for haematolo-
gists in the United Kingdom and beyond.89,90,91,92,93 In addi-
tion UKMF members have played an important role in the
development of the National Institute for Health Care Excel-
lence (NICE) guidelines for the management of myeloma
[NICE guideline (NG35)].94 More recently the UKMF has
worked with MUK to ensure that the patient voice is heard
clearly with respect to NICE determinations on the availabil-
ity of novel therapeutic agents, although the cost of these
agents often means that UK clinicians are unable to offer
therapy seen as optimal. This active role in advocacy started
with our support of the successful MUK appeal against the
initial decision of NICE to not recommend the use of borte-
zomib for relapsed patients. In the years since that time and
with the arrival of an expanding portfolio of novel agents for
myeloma this advocacy on behalf of MM patients has
become a major part of the work of UKMF.
Current status and future directions
As a consequence of the therapeutic revolution in MM, the
cohesive and inclusive working of clinical trialists and transla-
tion academic clinicians and scientists is key. At a national
level, we established the UK Myeloma Research Alliance
(UKMRA) through which our portfolio of clinical studies is
developed and delivered including the early-phase studies pre-
viously supported by MUK. The UKMRA activity continues to
thrive, with a run-through research strategy (early-phase trials
to inform late-phase trials) utilising its Concept and Access
Research Programme (CARP) accelerated trials platform
(funded by Myeloma UK). As part of this strategy, we have
incorporated our biomarker research to date into the design of
the trials to develop these from prognostic to predictive
biomarkers leading to adoption for everyday clinical use.
Many collaborative study groups as well as industry-driven
regulator clinical trials have defined the prognostics impact
of high-risk genetics.95,96 However, managing these patients
has yet to see a stepwise breakthrough in therapy delivery
and outcomes. Dr Martin Kaiser and Dr Matt Jenner are
leading the delivery of a novel study, the MUK9 OPTIMUM
trial, where newly diagnosed patients are being screened in
rapid real-time to define a molecularly high-risk population
and then to enrol these patients into a dose-dense delivery
schedule (NCT03188172). This proof-of-concept trial aims to
use well-established genomic prognostic biomarkers and
move to the next level and thus define it as a predictive bio-
marker to direct therapy. Moving forward with the clinically
challenging high-risk patients, we now enter a time of
immunotherapy, with monoclonal antibodies, CAR T-cells
and BiTE technologies that may bring hope of parity of out-
comes between standard and high-risk disease.97,98
Table II. Summary of myeloma UK phase 1 and 2 trials.
Trial Investigational agent Phase Status Recruitment Pharma partner Reference
MUK1 Bendamustine, thalidomide, dexamethasone 2a Closed 98 Napp Schey S et al.99
MUK3 Pabinostat/tosedostat 1b Closed 36 Chroma Popat R et al.100
MUK4 Vorinostat 2 Closed 16 Merck Jenner et al.101
MUK5 Carfilzomib, cyclophosphamide, dexamethasone 2b Closed 300 Amgen Yong K et al.101
MUK6 Pabinostat, bortezomib, thalidomide, dexamethasone 2 Closed 54 Novartis Popat et al.(a & b) 102,103
MUK7 Pomalidomide, cyclophosphamide, dexamethasone 2b Closed 102 Celgene Croft J et al.104
MUK8 Ixazomib, cyclophosphamide, dexamethasone 2b Closed 112 Takeda Hinsley et al.105
MUK9 Daratumumab, bortezomib, lenalidomide,
dexamethasone
2 Closed Screened 472
Randomised 108
Janssen/
Celgene
Shah V et al.59
MUK11 Reolysin 2a Closed 3 Celgene
MUK12 Selinixor, cyclophosphamide, dexamethasone 2 Open Karyopharm
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Current and proposed studies
As highlighted, the United Kingdom has been at the forefront
of assessing and validating MRD as a prognostic biomarker.
The United Kingdom is leading international research to
define the role of predictive biomarkers in the UKMRA Mye-
loma XV (RADAR) study (CI: Prof. Kwee Yong and Prof.
Mark Cook). Patients rendered MRD-negative through induc-
tion/ASCT will be studied to define whether a de-escalation of
post-transplant therapy is safe and effective whereas those who
remain MRD-positive post-ASCT will be studied for the
impact of treatment escalation, including immunotherapy.
The study aims to open for recruitment in Q3/4 of 2020.
It is clear from frailty clinical scores and biomarker
research that there is a clear unmet need in assessing how to
deliver the optimum treatment for TNE MM patients. The
UK Myeloma Research Alliance (UKMRA) has developed the
Myeloma XIV: FITNESS study (NCT03720041; CI Prof. Gra-
ham Jackson and Prof. Gordon Cook) where patients will be
randomised to a treatment-adaptive arm with therapy being
dose-reduced in accordance with the IMWG FS compared to
a conventional treatment-reactive arm where therapy will be
modified in relation to toxicity and tolerance (https://clinical
trials.gov/ct2/show/NCT03720041?cond=myeloma+XIV&dra
w=2&rank=1). The aim of the study will be the prevention
of treatment discontinuation and reduction of early death as
well as defining the impact on PFS and survivorship. Funded
by Cancer Research UK, the trial has opened for recruitment
in July 2020. This is one approach to the use of frailty scores
and there are currently seven other frailty-associated trials in
MM listed on clintrials.gov either recruiting or in set-up
(https://clinicaltrials.gov/ct2/results?cond=Myeloma&term=fra
ilty&cntry=&state=&city=&dist=).
Conclusion
Throughout history, the evolution of medicine has been typi-
fied by the advancement in biological knowledge at a pace
considerably ahead of therapeutic developments. In MM, in
the last two decades, the revolution has been a reversal of
this, in that therapeutic advances have led the biological dis-
coveries, and inspired the bench-to-bedside-and-back ethos.
The UK has played an important and central role in this rev-
olution and continues to contribute quality clinical and sci-
entific research that is primarily patient-facing, informing
practice and improving outcome.
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